Ivantis announced the FDA approval of the Hydrus microstent, designed to treat patients with mild to moderate primary open-angle glaucoma in conjunction with cataract surgery.
According to Ivantis President and CEO Dave Van Meter in a company press release, Ivantis intends to launch the device later this year.
The approval of the MIGS device was based on the results of the HORIZON trial, which included 556 mild to moderate glaucoma patients who underwent cataract surgery. The patients were randomly assigned to receive either cataract surgery plus the Hydrus microstent or (Read more...)
Uncategorized